Product Development Advisor for Caleco Pharma Corp., Harry Fong, Phd, Conducts Exclusive Webcast Interview With the Green Baron Report; New "Stock Pick" Coverage Initiated
BELLINGHAM, WASHINGTON--(Marketwire - October 20, 2009) - Caleco Pharma Corp. (the "Company") (OTCBB: CAEH)(FRANKFURT: T3R)(WKN: AON9YO) (www.calecopharmacorp.com) today announced that its Advisor for Product Development, Professor Harry Fong, has conducted an exclusive new audio-taped webcast interview so that the Company's shareholders and the investment community can learn more about the Company's recently developments and plans to confirm positive tests for its product aimed at liver health. Unrestricted access to the webcast is now available on the "Webcasts" page at www.TheGreenBaron.com. This webcast is also available at www.StrictlyStocks.com, "Where Wall Street speaks to the World."
The Green Baron Report also initiated coverage of Caleco Pharma as a new "Stock Pick" through its report released to members after the close of trading on Tuesday, October 13th, 2009 and is available at TheGreenBaron.com website. The report focused on how the Company's OTC formulation exhibited remarkably favorable effects in a human study of people with Hepatitis C, and how this liver health formulation could be widely marketed.
About The Green Baron Report
The Green Baron Report is a subsidiary of Evergreen Marketing. The Green Baron Report is an internet stock market newsletter that focuses on low priced stocks that appear to have significant upside potential. For more information about Evergreen Marketing, Inc. and their subsidiary The Green Baron Investors Society visit them on the web at http://www.EvergreenMarketingInc.com and http://www.TheGreenBaron.com. Our disclaimer can be viewed at http://www.thegreenbaron.com/Disclaimer.htm. Investors who wish to receive The Green Baron Report for free can join at http://www.thegreenbaron.com/Join.htm.
About Caleco Pharma Corp.
The Company's business plan is to develop its proprietary technology designed to treat moderate to severe liver maladies, such as elevated liver enzymes and the Hepatitis C viral infection, (the "Liver Health Formula") as an over-the-counter medication and as a United States Food and Drug Administration ("FDA") approved pharmaceutical. To date, the Company's intellectual property covering the Liver Health Formula comprises of patent applications in the United States, Europe and Canada and four European Drug Master File applications.
Caleco Pharma Corp. shares are traded in the United States on the OTC Bulletin Board (OTCBB: CAEH) and in Germany on the Frankfurt Stock Exchange (WKN: A0N9Y0/ Symbol:T3R.FSE).
This press release may contain, in addition to historic information, forward-looking statements. These statements may involve known and unknown risks and uncertainties and other factors that may cause the actual results to be materially different from the results implied herein. In particular, there are no assurances that: (i) the United States Patents and Trademarks Office will grant the Company a patent in connection with its current patent applications; (ii) the Company will be able to manufacture and produce its products or that its products will be effective; or (iii) it will be able to carry out any pre-clinical or clinical trials of its products. Readers are cautioned not to place undue reliance on the forward-looking statements made in this press release.